---
title: "China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Holdings’ Nine-Month Net Profit Falls to RMB 6.97 Billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303368599.md"
description: "CR Pharmaceutical Holdings, a subsidiary of China Resources Pharmaceutical Group, reported unaudited nine-month results ending September 30, 2026. Consolidated net profit fell to RMB 6.97 billion from RMB 7.56 billion the previous year, while profit attributable to parent-company owners declined to RMB 2.39 billion from RMB 2.56 billion. Conversely, revenue increased to RMB 203.53 billion from RMB 200.88 billion. Operating cash flow dropped significantly to RMB 4.85 billion from RMB 6.07 billion."
datetime: "2026-10-28T09:53:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303368599.md)
  - [en](https://longbridge.com/en/news/303368599.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303368599.md)
generator: "portal-rs"
---

# China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Holdings’ Nine-Month Net Profit Falls to RMB 6.97 Billion

-   CR Pharmaceutical Holdings, a wholly owned subsidiary of China Resources Pharmaceutical Group, reported unaudited nine-month results through September 30, 2026. \* Consolidated net profit fell to RMB 6.97 billion from RMB 7.56 billion a year earlier. \* Profit attributable to parent-company owners declined to RMB 2.39 billion from RMB 2.56 billion. \* Revenue rose to RMB 203.53 billion from RMB 200.88 billion. \* Operating cash flow dropped to RMB 4.85 billion from RMB 6.07 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261028-12385893), on October 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

- [China Resources Pharmaceutical Unit Secures Approval for RMB 10 Billion Corporate Bond Issuance](https://longbridge.com/en/news/305661943.md)
- [China Resources Pharmaceutical Completes RMB 800 Million Medium-Term Note Issuance](https://longbridge.com/en/news/302856714.md)
- [China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Commercial’s Nine-Month Net Profit Rises to RMB 1.75 Billion](https://longbridge.com/en/news/303715107.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**